DAGRS: directed antigonists to cancer cell growth signals
US11299516B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Jul 13, 2017 |
| Grant date | Apr 12, 2022 |
| Priority date | — |
| Expiry date | Jul 17, 2037 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG16B40/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention describes a unique method of treating cancer with the administration of an improved DAGRS™ construct which functions as a humanized agent specifically targeting cancer cells in vivo. A specific DAGRS™ is described constructed of a humanized drug delivery biologic, carboxyl to an Apoptin fragment consisting of Apoptin's proline-rich SH3-binding fragment, a spacer, and a MAP kinase (MAPK) phosphorylation site, in replacement of the SH3-binding domain at HIV-1 TAT's amino terminus. Apoptin is a viral protein with incumbent immunogenicity and toxicity in humans. Improved DAGRS™ constructs are described that replace the viral VP3 peptide with human AKT peptide or derivative, all equivalently spaced 11 amino acids from the initial proline to the beginning of the MAPK phosphorylation site, through which technology the DAGRS™ is fully humanized. DAGRS™ provide for improved bioavailability, enhanced specific activity, and low toxicity for in vivo treatment of cancer. DAGRS™ are a superior method for targeting any oncogene with an inhibitory peptide.An algorithm for “humanization” is described through which human functional equivalent(s) to viral product(s) are identifi…
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.